Banque Cantonale Vaudoise’s TherapeuticsMD TXMD Stock Holding History

Banque Cantonale Vaudoise’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	7	–	–	﹤0.01%	929
2025 Q4	$0	Hold	7	–	–	﹤0.01%	878
2025 Q3	$0	Buy	+7	New	+$8	﹤0.01%	863
2024 Q2	–	Sell	-1,000	Closed	-$2K	–	1065
2024 Q1	$2K	Hold	1,000	–	–	﹤0.01%	973
2023 Q4	$2K	Hold	1,000	–	–	﹤0.01%	1001
2023 Q3	$3K	Hold	1,000	–	–	﹤0.01%	1159
2023 Q2	$4K	Hold	1,000	–	–	﹤0.01%	1145
2023 Q1	$4K	Hold	1,000	–	–	﹤0.01%	1151
2022 Q4	$6K	Hold	1,000	–	–	﹤0.01%	1136
2022 Q3	$7K	Hold	1,000	–	–	﹤0.01%	1172
2022 Q2	$10K	Hold	1,000	–	–	﹤0.01%	1186
2022 Q1	$19K	Hold	1,000	–	–	﹤0.01%	1157
2021 Q4	$18K	Buy	1,000 +200	+25%	+$5.99K	﹤0.01%	1194
2021 Q3	$30K	Buy	800 +200	+33%	+$8.88K	﹤0.01%	1117
2021 Q2	$36K	Buy	600 +200	+50%	+$12.1K	﹤0.01%	1089
2021 Q1	$27K	Hold	400	–	–	﹤0.01%	1054
2020 Q4	$24K	Buy	+400	New	+$27.3K	﹤0.01%	1005

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Cantonale Vaudoise's TXMD Position: Q1 2026 in Review

Banque Cantonale Vaudoise held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 7 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #929.

Banque Cantonale Vaudoise first reported a position in TXMD in Q4 2020 and has held it in 17 quarters since. The position peaked at $36K in Q2 2021. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

Banque Cantonale Vaudoise held 7 shares of TherapeuticsMD worth $0 as of Q1 2026.
Banque Cantonale Vaudoise left its TherapeuticsMD share count unchanged in Q1 2026.
TherapeuticsMD made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #929 holding.
Banque Cantonale Vaudoise first reported a position in TherapeuticsMD in Q4 2020 and has held it in 17 quarters since.
Banque Cantonale Vaudoise's TherapeuticsMD position peaked at $36K in Q2 2021.
49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.